CNS Pharmaceuticals (NASDAQ: CNSP) , focused on innovative cancer therapies for brain and central nervous system cancers, recently participated in ...

Segment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael Weller Access the segment ...

Detailed price information for Cns Pharmaceuticals Inc (CNSP-Q) from The Globe and Mail including charting and trades.

HOUSTON, TX / ACCESSWIRE / November 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a ...

CNS Pharmaceuticals (NASDAQ: CNSP) announced that it received an exception from the nasdaq Hearings Panel, granting the company until March 11, 2025, to meet the minimum bid price requirement under ...

CNS Pharmaceuticals is currently developing a portfolio of anti-cancer drugs, with its lead candidate, Berubicin, being an innovative anthracycline believed to be the first of its kind to cross ...

As CNS Pharmaceuticals moves forward with its offerings and the continued development of Berubicin, the path ahead will be pivotal. Investors and stakeholders will be watching closely to see how the ...

CNS Pharmaceuticals is currently developing a portfolio of anti-cancer drugs, with its lead candidate, Berubicin, being an innovative anthracycline believed to be the first of its kind to cross the ...

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on developing treatments for cancers affecting the brain and central nervous system, has announced that it has entered into ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment ...